article thumbnail

FTC targets middlemen in generic drug shortages probe

pharmaphorum

The FTC is investigating wholesalers and other middlemen in the pharma supply chain to assess their possible role in worsening shortages of generic medicines

article thumbnail

Opinion: I went on a mind-boggling journey to get my son’s ADHD medication covered by insurance — twice

STAT

As a former editor for diabetes publications, I knew that insurance companies regularly switched people from one brand of insulin to another, or from a name brand of insulin to a generic. However, I had used generic medicine for my blood pressure without a problem, so I hoped for the best with this switch.

Insurance 117
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NHS drug shortages are partly a political failure | Letters

The Guardian - Pharmaceutical Industry

Roared on by the pharmaceutical industry, ministers have been using trade talks with India to push for agreement on new, extremely restrictive patent rules that would severely undermine its generic medicines industry.

article thumbnail

STAT+: Generic makers fall short when providing access to low- and middle-income countries, analysis finds

STAT

A handful of the largest purveyors of generic medicines have made only halting progress to ensure their drugs are accessible for patients in low- and middle-income countries, a new analysis found.

article thumbnail

The Guardian view on India-UK trade talks: don’t make it harder for the health service | Editorial

The Guardian - Pharmaceutical Industry

Britain is pushing for patent changes that could increase the cost of Indian generic drugs, diverting more of the NHS budget to big pharma India is known as the “ pharmacy of the world ”, supplying vital generic medicines at low prices to health services including the NHS.

article thumbnail

STAT+: FTC challenges several big drugmakers over inaccurate or improper patent listings

STAT

The move comes two months after the FTC issued a policy statement noting some drug companies have failed to follow requirements for listing patents in the Food and Drug Administration’s Orange Book in hopes of thwarting competition from lower-cost generic medicines. Continue to STAT+ to read the full story…

article thumbnail

STAT+: FTC warns drugmakers they can face legal action over improper patent listings

STAT

In explaining its new policy statement , the FTC noted that some drug companies have failed to follow requirements for listing patents in the so-called Orange Book in hopes of thwarting competition from lower-cost generic medicines.